schizophrenia

Researchers around the world are on a mission to bank biological samples from millions of people. So far, these efforts have disclosed the effects of arsenic exposure on the genome, supported development of early cancer diagnostics, and even revealed the ideal timing for COVID-19 boosters.

A newly developed drug stabilizes dopamine and serotonin levels using a novel mechanism. It effectively treats psychosis in patients with schizophrenia, and researchers are testing its efficacy for Parkinson’s disease as well.

Wide adoption and regimen compliance are two reasons for easier administration, whether with COVID or schizophrenia